Motley Fool: Pfizer and Merck are keeping the Dow alive

Featured Story

Motley Fool: Pfizer and Merck are keeping the Dow alive

February 15, 2014 4:25 am by | 0 Comments

Pharmaceutical giant Pfizer Inc., which has its largest worldwide research site in Groton, is the third best-performing company so far this year among the 30 bellwether stocks that comprise the Dow Jones Industrial Average.
According to an article titl…


ICYMI: Here are the 5 top stories in March on MedCity News

ICYMI: Here are the 5 top stories in March on MedCity News

March 31, 2014 4:29 pm by | 0 Comments

5. Now that’s a security breach: England’s entire healthcare data set uploaded to Google servers @JuliaHCox @CLeslieMP so HES data uploaded to ‘google’s immense army of servers’ , who consented…


Tech PR firm takes on Merck to save the life of an employee with kidney cancer

Tech PR firm takes on Merck to save the life of an employee with kidney cancer

March 23, 2014 12:00 pm by | 0 Comments

Last November, Mikaela Knapp was diagnosed with an aggressive strain of kidney cancer, which metastasized to her brain. Knapp is 25. Prior to her diagnosis, Knapp had worked as an account…



Merck digital health arm hopes to generate big data healthcare insights

Merck digital health arm hopes to generate big data healthcare insights

March 10, 2014 5:55 am by | 2 Comments

It’s been more than one year since Merck (NYSE: MRK) launched a digital health arm to develop big data insights in healthcare to guide therapies and develop patient-centered outcomes. CMIO…


Bayer, Novartis, others interested in Merck’s consumer healthcare unit

Bayer, Novartis, others interested in Merck’s consumer healthcare unit

February 19, 2014 4:12 pm by | 0 Comments

NEW YORK/LONDON (Reuters) – A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc’s consumer healthcare business, as they…


Merck latest drugmaker to look for copy Sanofi’s diabetes drug Lantus

Merck latest drugmaker to look for copy Sanofi’s diabetes drug Lantus

February 10, 2014 12:16 pm by | 0 Comments

(Reuters) – U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi’s top-selling insulin treatment Lantus, increasing the long-term threat to the French company’s…


Merck ordered to pay $100 million in NuvaRing settlement

Merck ordered to pay $100 million in NuvaRing settlement

February 7, 2014 10:05 am by | 0 Comments

Feb 7 (Reuters) – Merck & Co said on Friday it has agreed to pay $100 million to resolve all U.S. product liability lawsuits involving its NuvaRing contraceptive product. Merck,…


Merck just misses financial goals while facing competition from generics

Merck just misses financial goals while facing competition from generics

February 5, 2014 7:15 am by | 0 Comments

(Reuters) – Merck & Co Inc’s quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but shares rose 1.5 percent on enthusiasm for newly…



Merck allergy drug deemed safe by FDA for adults

Merck allergy drug deemed safe by FDA for adults

January 28, 2014 1:58 pm by | 0 Comments

(Reuters) – Merck & Co’s experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel…


Can better care plans increase adherence between patient office visits? Merck’s picks will see

Can better care plans increase adherence between patient office visits? Merck’s picks will see

January 27, 2014 4:27 pm by | 1 Comments

One of the frustrating aspects of getting patients to follow a care plan is the inability to have a clear window to patient activity between office visits. If care providers…


FDA says no serious side effects with Merck allergy pill

FDA says no serious side effects with Merck allergy pill

January 24, 2014 12:46 pm by | 0 Comments

(Reuters) – No serious safety concerns were raised over Merck & Co’s experimental pill for ragweed allergies, according to FDA documents Friday, ahead of a meeting next week of outside…


In Merck patient adherence throw down, 5 teams reimagine care plans for diabetes, heart disease patients

In Merck patient adherence throw down, 5 teams reimagine care plans for diabetes, heart disease patients

January 20, 2014 6:04 pm by | 0 Comments

One of the biggest challenges to improving care for patients with diabetes and heart disease is figuring out the best tools for those patients. The problem is, there’s no such…


Merck’s new blood clot prevention drug gets support from FDA

Merck’s new blood clot prevention drug gets support from FDA

January 15, 2014 4:20 pm by | 0 Comments

(Reuters) – Merck & Co Inc’s experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart…


Merck’s anti-blood clot drug shows ‘robustly positive’ results, approval expected

Merck’s anti-blood clot drug shows ‘robustly positive’ results, approval expected

January 13, 2014 8:57 am by | 0 Comments

(Reuters) – Merck & Co Inc’s experimental blood clot-preventing drug vorapaxar should be approved, based on “robustly positive” clinical trial results, according to a preliminary review of the data by…


Going beyond the pill, Merck launches weight management business

Going beyond the pill, Merck launches weight management business

December 20, 2013 1:09 pm by | 4 Comments

There’s been a growing trend among pharmaceutical companies to develop services that can complement or amplify their drug development efforts. In a move that combines that trend with the battle…


French watchdog fines Merck $21 M over ‘smear campaign attack’ against generic drug

French watchdog fines Merck $21 M over ‘smear campaign attack’ against generic drug

December 19, 2013 9:08 am by | 0 Comments

PARIS (Reuters) – The French competition authority said on Thursday it had fined Schering-Plough, now owned by Merck, 15.3 million euros ($21 million) over what it called a smear campaign…